Cargando…

Prevalence of Amyloidosis in Korea

BACKGROUND: The aim of this study was to assess in amyloidosis prevalence in Korea between 2006 and 2015. METHODS: Primary diagnoses related to amyloidosis, regardless of subtype, were collected from the Korean National Health Insurance Service from 2006 through 2015. RESULTS: Overall, the age-stand...

Descripción completa

Detalles Bibliográficos
Autores principales: Seo, Su Ra, Jang, Shin Yi, Lee, Ga Yeon, Choi, Bareun, Chun, Heeran, Cho, Eun Jeong, Cho, Sung-il
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5588743/
https://www.ncbi.nlm.nih.gov/pubmed/28877709
http://dx.doi.org/10.1186/s13023-017-0705-2
Descripción
Sumario:BACKGROUND: The aim of this study was to assess in amyloidosis prevalence in Korea between 2006 and 2015. METHODS: Primary diagnoses related to amyloidosis, regardless of subtype, were collected from the Korean National Health Insurance Service from 2006 through 2015. RESULTS: Overall, the age-standardized prevalence of amyloidosis was 0.93 (95% confidence interval (CI) 0.81, 1.04) persons per 100,000 persons in 2006 and 1.91 (95% CI 1.78, 2.05) persons per 100,000 persons in 2015. This included an increase from 0.43 (95% CI 0.35, 0.51) to 1.04 (95% CI 0.94, 1.14) persons per 100,000 persons in men and from 0.49 (95% CI 0.40, 0.57) to 0.87 (95% CI 0.77, 0.96) persons per 100,000 persons in women. In particular, the age-standardized prevalence of amyloidosis showed a greater increase in patients aged 65 years or older and in patients aged 45–64 years than in patients aged 20–44 years, for both men and women. CONCLUSIONS: The overall age-standardized prevalence of amyloidosis was approximately 2 persons per 100,000 persons in 2015. The overall age-standardized prevalence of amyloidosis increased between 2006 and 2015, especially in individuals aged 45–64 and older than 65 years. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1186/s13023-017-0705-2) contains supplementary material, which is available to authorized users.